62936-33-8

Basic information

• Product Name: ETHYL 4-PHENOXYBENZOYLFORMATE
• Synonyms: ETHYL 4-PHENOXYBENZOYLFORMATE;Oxo-(4-phenoxyphenyl)acetic acid ethyl ester
• CAS NO: 62936-33-8
• Molecular Formula: C₁₆H₁₄O₄
• Molecular Weight: 270.28
• Mol File: 62936-33-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 390.1°C at 760 mmHg
• Flash Point: 172.1°C
• Appearance: /
• Density: 1.185g/cm³
• Vapor Pressure: 2.71E-06mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: ETHYL 4-PHENOXYBENZOYLFORMATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-PHENOXYBENZOYLFORMATE(62936-33-8)
• EPA Substance Registry System: ETHYL 4-PHENOXYBENZOYLFORMATE(62936-33-8)

Safety Data

• Hazardous Substances Data: 62936-33-8(Hazardous Substances Data)

Usage

General Description

ETHYL 4-PHENOXYBENZOYLFORMATE is a chemical compound with the molecular formula C15H14O4. It is a formate ester of 4-phenoxybenzoyl acid and ethyl alcohol. ETHYL 4-PHENOXYBENZOYLFORMATE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been investigated for its potential use as a sunscreen agent due to its UV-absorbing properties. ETHYL 4-PHENOXYBENZOYLFORMATE is a white solid that is soluble in organic solvents and is considered to be stable under normal conditions. However, it may decompose under high temperatures and is incompatible with strong oxidizing agents.

InChI:InChI=1/C16H14O4/c1-2-19-16(18)15(17)12-8-10-14(11-9-12)20-13-6-4-3-5-7-13/h3-11H,2H2,1H3

Upstream product

• 101-84-8 diphenylether 
• 4755-77-5 Ethyl oxalyl chloride 
• 101-55-3 4-Bromodiphenyl ether 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 79478-16-3 (4-Phenoxy)phenylglyoxylsaeure 
• 1613439-82-9 N-(3-(N,N-dimethylaminocarbonylphenyl))-2-oxo-2-(4-phenoxyphenyl)acetamide 
• 129168-44-1 2-oxo-2-(4-phenoxyphenyl)acetyl chloride 
• 1359764-17-2 C₁₆H₁₅NO₄ 
• 1359764-54-7 C₂₁H₂₁N₃O₂ 
• 1359764-50-3 C₂₁H₂₀ClN₃O₂ 
• 1359764-42-3 C₂₁H₂₂ClN₃O₂ 
• 1359764-32-1 C₂₁H₂₁Cl₂N₃O₂ 
• 1359764-26-3 C₂₁H₂₃N₃O₃ 
• 1359764-22-9 C₂₁H₂₂ClN₃O₃ 
• 1177277-27-8 2-amino-2-(4-phenoxyphenyl)ethanol 
• 250602-60-9 ethyl (E)-2-(hydroxyimino)-2-(4-phenoxyphenyl)acetate 
• 1026622-55-8 [(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-(4-phenoxy-phenyl)-acetic acid ethyl ester 
• 250601-08-2 (Z)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-2-(4-phenoxyphenyl)acetic acid 

Relevant articles and documents

Sulfonium salt photoinitiator, preparation and application methods thereof, and photocuring composition comprising same

The invention provides a sulfonium salt photoinitiator, preparation and application methods thereof, and a photocuring composition comprising the same. The sulfonium salt photoinitiator has a structure shown as the formula (I). The sulfonium salt photoini

Cationic Ir/Me-BIPAM-catalyzed asymmetric intramolecular direct hydroarylation of α-ketoamides

Asymmetric intramolecular direct hydroarylation of α-ketoamides gives various types of optically active 3-substituted 3-hydroxy-2-oxindoles in high yields with complete regioselectivity and high enantioselectivities (84-98 % ee). This is realized by the use of the cationic iridium complex [Ir(cod) 2](BArF4) and the chiral O-linked bidentate phosphoramidite (R,R)-Me-BIPAM. Carbon's got a brand new bond: Asymmetric intramolecular direct hydroarylation of α-ketoamides gives various optically active 3-substituted 3-hydroxy-2-oxindoles in high yields with complete regioselectivity and high enantioselectivities. This is realized by the use of an asymmetric cationic iridium complex formed in situ (see Scheme).

NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS

The present invention relates to non-steroidal progesterone receptor modulators of the general formula 1, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compositions which comprise these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.